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Abstract 
Background 
Clozapine is the only drug approved for treatment resistant schizophrenia.  There is evidence 
that clozapine is underutilized. 
Aims 
To evaluate the initiation and discontinuation of clozapine at Landspitali University Hospital 
in Iceland and the prevalence of antipsychotic polypharmacy in clozapine-treated patients.   
Methods 
The study is a part of an ongoing longitudinal study of schizophrenia in Iceland.  We 
identified 201 patients on clozapine or who have been on clozapine by using a keyword 
search in the electronic health records and by reviewing their medical records.   
Results 
Mean age at first treatment with clozapine was 37.8 years.  Mean follow-up period on 
clozapine was 11 years.  After 20 years of treatment 71.2% of patients were still on clozapine.   
After one year of treatment 84.4% of patients were still receiving clozapine treatment.  We 
estimate that 11.4% of patients with schizophrenia in Iceland are taking clozapine and that 
16% have been treated with clozapine at some point.  Polypharmacy is common, since nearly 
2/3, 65.6%, of patients taking clozapine use at least one other antipsychotic and 16.9% are 
also receiving depot injections. 
Conclusions 
We need to increase the awareness of psychiatrists in Iceland with regard to treatment with 
clozapine, since only about half of the estimated population of patients with treatment 
resistant schizophrenia in Iceland have ever been treated with clozapine. Nearly two thirds of 
patients who are prescribed clozapine in Iceland remain on it long-term. 
Keywords: schizophrenia, treatment-resistant, clozapine, polypharmacy, antipsychotics  
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Introduction 
Around 20-30% of patients with schizophrenia prove to be treatment resistant and 
clozapine has been demonstrated to be the drug of choice to offer those patients (1).  
Treatment resistance has been defined as failure to respond to two or more antipsychotics 
(one of which should be an atypical) when given at an adequate dose for at least six to eight 
weeks (2, 3). Clozapine has also been found to be superior to other antipsychotic medications 
for non-treatment resistant schizophrenia in a meta-analysis (4).  In addition to having an 
indication for treatment resistant schizophrenia, clozapine also has FDA approval for the 
prevention of recurrent suicidal behavior, its effectiveness in this indication having been 
demonstrated in the international suicide prevention trial (InterSePT) (5). 
There is evidence that clozapine remains underutilized despite being the only drug 
approved for treatment resistant schizophrenia (6, 7).  Clozapine use in schizophrenia varies 
widely between countries: from being as high as 26.9% (8) in Taiwan, 26.7% in China (8), 
15,2% in Australia (9), 10.1% in Denmark (10), to as low as 4.4% in the USA (11).  It is not 
well understood why clozapine appears underutilized in some countries despite the strong 
evidence for its efficacy in treatment resistant schizophrenia.  Possible explanations include 
the strict hematological monitoring requirements and the potential for rare but potentially 
serious side effects such as agranulocytosis, myocarditis and seizures, and more common ones 
such as weight gain and type 2 diabetes mellitus.   
Clozapine has been established as a cost effective treatment for treatment resistant 
schizophrenia.  Patients on clozapine have reduced frequency of hospital admissions (12).  
Schizophrenia is a disorder known in all settings and cultures. The prevalence of 
schizophrenia is more geographically varied than previously assumed, but it is estimated that 
7 individuals per 1000 will be affected, but gender, urbanicity, latitude an migration have 
been shown to influence incidence rates (13, 14).   
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Aims of the study 
The aim of the study is to describe clozapine treatment of patients with schizophrenia 
in Iceland; specifically to describe the proportion of patients taking clozapine, the pattern of 
discontinuation over time and the frequency of antipsychotic polypharmacy in patients treated 
with clozapine. 
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Materials and methods 
Landspitali University Hospital (LUH) started to use electronic health records (EHR) in 1998 
but older records are available on paper.  Subsequently the proportion of medical, psychology 
and nursing data in EHR has been steadily growing and currently includes almost all patient 
data in the hospital.  
This study constitutes a part of an ongoing longitudinal study in the LUH department 
of psychiatry focusing on patients with schizophrenia and bipolar disorder.  Patients have 
been recruited to the study in several waves from 1986 – 2014.  The majority of inpatients and 
outpatients at LUH with schizophrenia or bipolar disorder have been approached to take part 
in the study.  Most of the patients were recruited between the years 2000 and 2004.  In this 
study we looked at patients from the LUH study who were alive on 1.1.2003 and had a 
confirmed diagnosis of schizophrenia according to the “Schedules for Affective Disorder and 
Schizophrenia-Lifetime version” (SADS-L) (15).  In total 611 patients met the inclusion 
criteria.  
  LUH is the only tertiary hospital for mental health services in Iceland and it also 
provides secondary psychiatric services and inpatient beds in psychiatry for over 90% of the 
Icelandic population.  Therefore the overwhelming majority of Icelandic patients with 
treatment resistant schizophrenia who have ever been on clozapine have been in regular or 
temporary contact with the mental health services or other services of LUH.  
To identify patients that have used clozapine we used a keyword search in the EHR 
for the text “clozapin”, “closapin” and “Leponex”.   The “e” at the end of clozapin was 
omitted because of possible spelling errors in the E-HR but a keyword search of “clozapin” 
will find “clozapin” and “clozapine”.  “closapin” with an “s” was also used in the keyword 
search.  Leponex was the only brand name of clozapine in Iceland until May 2014 when the 
generic “Clozapine Actavis” was introduced to the market.  All medical notes with the 
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clozapine keywords were reviewed to assess whether clozapine had been used.  For patients 
that had insufficient documentation of prior psychiatric illness and medical use in the EHR 
the paper medical records were reviewed for clozapine use.  The time period of clozapine use 
was documented.  We identified 201 patients with schizophrenia and 23 patients with bipolar 
disorder that had used clozapine.   
Information on the first period of clozapine treatment for patients with schizophrenia 
was available for 195 patients out of 201.  We had the exact date of clozapine initiation for 
167 patients.  For 28 patients it was not possible to set an exact date for the initiation of 
clozapine treatment but from medical records it was possible estimate the time from a couple 
of weeks to a couple of months.  Of those 28 patients, 24 patients started clozapine before 
1998 which is when LUH started using EHR.   
When assessing the proportion of patients continuing on clozapine we used a Kaplan-
Meyer survival analysis.  If a patient had tried clozapine, then stopped clozapine and then 
restarted then the start of clozapine treatment was defined from the last start of clozapine 
treatment.  Patients that died during follow up or were still taking clozapine at the end of 
follow up were censored from time of death or end of follow up. 
In the clozapine ever discontinuation analyses we examined the time from the first 
treatment with clozapine until the patient discontinued clozapine treatment regardless if he 
later restarted clozapine treatment.   
When analyzing concomitant medication use while patients were taking clozapine we 
considered the last known medication regime stated in the medical notes before the end of 
follow-up or the date that the patient discontinued.  It may take up to 6 months of clozapine 
treatment to observe full improvement in positive symptoms (11).  Dosing adjustment of 
clozapine therefore can take even longer so patients had to have been on clozapine for at least 
one year to be included.  There was no minimum dose of clozapine so patients using low 
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doses of clozapine were also included.  In total we had detailed medication information for 
154 patients with schizophrenia and 145 out of them used 100 mg or more of clozapine.    
 We used the mean clozapine dose prescribed in the cohort and the total clozapine sales 
in 2013 to estimate how many patients in Iceland with schizophrenia had used clozapine that 
year, assuming that the use of clozapine for other disorders than schizophrenia and bipolar 
disorder was negligible. 
Data used to assess antipsychotic drug use in Iceland in 2013 was collected from the 
Icelandic Medicines Agency.  
The study was reviewed and approved by the Icelandic National Bioethics Committee 
(FS-02-041(03-030)) and the Data Protection Authority (2009090737ÞS).    
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Results 
Age at first treatment with clozapine 
The mean age at first treatment with clozapine was 37.8 years (SD=12.2), 36.5 years 
(SD=12.5) for males and 41.0 years (SD=11) for females.  On average males started clozapine 
treatment 4.5 years earlier than females (p=0.008).   
Figure 1 describes the age of patients when clozapine treatment was first started.  The mean 
was 37.8 (SD=12.2) with a range of 16.4 to 69.6 years.    
 
Figure 1 approximately here 
 
The mean follow-up time on clozapine was 11.1 (SD=9) years for males and 10.9 
(SD=8.5) years for females.   
 
Discontinuation of clozapine 
Figure 2 is a Kaplan-Meier survival graph that displays the proportion of patients that 
were on clozapine the first 20 years of treatment.  After 1 year of treatment 84.4% of patients 
were still on clozapine and after 2 years 81.8% of patients were still on clozapine.  After a 20 
year follow up 71.2% of patients were still on clozapine, 71.5% of the males and 70.1% of the 
females.   
We also estimated the proportion of patient’s ever discontinuing clozapine treatment 
after the first start of clozapine treatment with a Kaplan-Meier survival estimate.  One year 
after the first start of clozapine treatment then 17.6% of patients had discontinued clozapine 
treatment and two years after start of clozapine treatment then 22.7% of patients had 
discontinued clozapine treatment.  Eighteen patients restarted clozapine treatment after having 
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discontinued clozapine use and 14 of them were still on clozapine at the end of follow-up or 
when they died.     
 
Figure 2 approximately here 
 
Most patients that come off clozapine do so early on.  In the first 6 months 33 patients 
out of those 68 who ever discontinued it (48.5%) came off clozapine, 3 had died and one was 
censored because of follow up time less than one year.  Two years after the first start of 
clozapine treatment 49 patients had stopped clozapine treatment (72% of total 
discontinuation), 4 had died and 2 were censored.   Clozapine discontinuation did though 
continue to occur at a slower rate during subsequent years of treatment 
 
Clozapine dosing and concomitant treatments 
The mean dose of clozapine was 304.6 mg (SD=172 mg) and the median dose was 
262.5 mg, range 25 - 800 mg.   
Table 1 describes polypharmacy in the cohort.  About one third of the patients 
received clozapine as their only antipsychotic.  About two thirds of patients (65.5%) were 
prescribed more than one antipsychotic.  The average World Health Organization defined 
daily dose (DDD) of antipsychotics was 1.67 in the cohort (16).  As the number of regular 
antipsychotic drugs increased the DDD also increased.  The average DDD for patients whose 
sole antipsychotic was clozapine was 1.01.  For patients on four or more antipsychotics the 
average DDD was 3.01. 
 
Table 1 approximately here 
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When analyzing polypharmacy in the cohort we found 16 different antipsychotic 
drugs used with clozapine.  Chlorpromazine was the most commonly used antipsychotic in 
oral preparations in addition to clozapine treatment with 16 patients (10.4%) receiving 
chlorpromazine with clozapine.   
Table 2 describes the depot injections used with clozapine. 6.5% of all patients 
receiving clozapine also received perphenazine depot injections and 5.8% received 
Risperidone depot injections.   In total there were 26 patients out of 154 (16.9%) that received 
depot antipsychotics alongside their clozapine tablets.  One patient received two depot 
injections with clozapine.  
 
Table 2 approximately here 
 
Regular use of benzodiazepine drugs (ATC codes NO3AE** and N05BA**) was 
common in the cohort but 69 patients out of 154 (44.8%) used them daily.  The average age of 
patients on benzodiazepine drugs was 53.8 years and the average age for patients not using 
benzodiazepine drugs daily was 50.0 years.  Clonazepam was the most commonly used 
benzodiazepine, 45 patients out of 154 (29.2%) used it daily.  Antidepressants use was also 
common with 74 patients out of 154 (48.1%) using antidepressants daily, sertraline being the 
most common antidepressant (16.2%). 
Antipsychotic sales in Iceland 
 
Table 3 approximately here 
 
Table 3 describes antipsychotic sale figures in Iceland in 2013. Clozapine was the fifth 
most common antipsychotic in Iceland with 224 DDD and a market share of 6.2%.   
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The average clozapine dose in the group of patients with schizophrenia was 304.6 mg.  
There were 23 patients out of 224 (10.3%) with SADS-L confirmed bipolar disorder that had 
used clozapine.  The average dose of clozapine for those with bipolar disorder was 215.8 mg 
(SD=150) and the median dose was 200 mg, range 50 – 500 mg.   
We estimated that patients with schizophrenia use 92.7% of clozapine prescribed and 
patients with bipolar disorder use around 7.3% of total clozapine sold (23 / 224) x (215.8 mg / 
304.6 mg).  The total population in Iceland at the end of 2013 was 325,671 and the population 
of persons aged 15 years and older was 255,391(17).  We use the prevalence of schizophrenia 
of 0.7% (13, 14) and extrapolate that to the population 15 years and older then we can 
estimate that there were 1,788 (0.7% x 255.391) patients with schizophrenia in Iceland in 
2013.  Total mg of clozapine sold in 2013 in Iceland was 24.524.967 mg.  We estimated that 
the total amount of clozapine sold for schizophrenia was 22.734.644 mg (92.7% x 24.524.967 
mg).  Dividing the total amount of clozapine sold with the mean dose used in schizophrenia in 
Iceland gives us an estimated number of total patients using clozapine in 2013 as 204 
(22.734.644) / (304.6 x 365 days).  We know that 71.2% of patients stay on clozapine so 
using that percentage we can estimate the number of patients with schizophrenia that had ever 
used clozapine in 2013 to be 287 (204 / 71.2%).  We therefore estimate the proportion of 
patients with schizophrenia in Iceland using clozapine in 2013 to be 11.4% (204 / 1.788) and 
the proportion of patients with schizophrenia that have ever used clozapine to be 16% (204) / 
(1.788 x 71.2%).  
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Discussion 
The proportion of patients that remained on clozapine during 20 years of follow up in 
the study proved to be very high or 71.2%.  In view of the multiple side-effects of clozapine, 
this high proportion appears to indicate that clozapine is an effective drug for patients with 
treatment resistant schizophrenia in our cohort.  The high proportion may also to a degree 
reflect the fact that there is no other available drugs indicated for treatment resistant 
schizophrenia.  One year after starting clozapine treatment 84.4% of patients remained on 
clozapine which is higher than in a study by Essock et al. where 74% of patients were still 
taking clozapine after one year of treatment (18).  Two years after starting treatment the 
proportion still taking clozapine was 81.8% which is higher than in the study by Essock et al 
where it was 66%.  In a naturalistic Chinese study which compared the discontinuation rate of 
clozapine to other antipsychotics one year after starting treatment in early stage schizophrenia, 
62.3% of patients remained on clozapine (19).  We can only speculate why the proportion is 
even higher in Iceland. This may be the result of several factors: most patients start on 
clozapine as inpatients, the mean dose of clozapine is fairly low, it is often prescribed only in 
the evening to reduce daytime sedation, blood monitoring is less stringent than in some 
countries such as the UK and the US, and finally, continuity of care is probably overall more 
common than in larger societies.   
In the clozapine phase of the CATIE trial the time to discontinuation was significantly 
longer for clozapine than for other antipsychotics. Despite the treatment resistance 
requirement and the multiple side effects many patients experience on clozapine treatment, 
patients with schizophrenia tend to stay on it longer than on other antipsychotics (20). 
The mean clozapine dose of 304 mg a day used in our sample is a similar to the 
average dose of 284 mg in Europe as reported by Fleischacker and colleagues (21).  The same 
study reported a higher mean clozapine dose in the USA of 444 mg daily.  In a recent study 
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by Nielsen and colleagues the mean clozapine dose in a Danish cohort was a reported to be 
382 mg (10).  In a small Swedish cohort (n = 33) the clozapine dose was recently reported to 
be somewhat higher and closer to doses seen in USA or 460 mg (22).  
Polypharmacy was common in our cohort with 65.6% of patients using clozapine and 
at least one another antipsychotic which was about the same percentage as recently reported 
in the Danish cohort,  64.2% (10).  There is though little evidence to support such widespread 
antipsychotic polypharmacy in schizophrenia treatment, as was observed in the cohort (23).   
The proportion of patients defined as treatment resistant has been estimated in the 
range of 20-30% (1).  We estimate that 16% of all patients with schizophrenia in Iceland have 
at some point been treated with clozapine. This is somewhat lower than the estimated 
proportion of patients with treatment resistant schizophrenia.  This suggests that psychiatrists 
need to be more alert in considering clozapine as an option and address issues that might 
contribute to the low use of clozapine.     
Clinicians might overestimate the risk benefit ratio of agranulocytosis and associated 
mortality versus the benefits of treatment.  Even though clozapine very rarely can cause fatal 
agranulocytosis it has been shown that clozapine use reduces total mortality of patients with 
schizophrenia (24) and reduces the risk of suicide attempts (5).  The risk of agranulocytosis is 
estimated to be around 0.68% (25).  Mortality in agranulocytosis has been estimated to be 
about 2.7%-3.1% and therefore the absolute mortality of patients on clozapine because of 
agranulocytosis is very low or around or 0.02% (25, 26).  Life expectancy in schizophrenia is 
reported to be reduced by 22.5-25 years, which is about 40% of their total adult years, due to 
poor physical health and a high suicide rate (27).  If we set the low risk of mortality due to 
agranulocytosis in the context of increased survival by those on clozapine and that living with 
schizophrenia reduces adult years by about 40%, then the absolute mortality rate of 0.02% or 
one in 5000 due to agranulocytosis seems clinically insignificant.  We can also compare the 
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mortality for agranulocytosis to dying in an automobile accident in Iceland.  The average 
number of people dying in a automobile accident in Iceland in 1995-2014 was 16,3 (28).  The 
mean population in Iceland in the years 1995-2014 was 296.004(17).  The risk of dying in an 
automobile accident over a 40 year period is estimated to be 0.22% (1-((1-16.3/296.004)40)).  
We therefore estimate that it is 10 times more likely that a patient with schizophrenia who is 
taking clozapine dies in an automobile accident in adulthood than from agranulocytosis.  
Neutrophil monitoring for patients on clozapine has not been shown to be cost effective which 
reflects the very low mortality of agranulocytosis (29).  In light of the above we recommend 
that the risk of agranulocytosis should not be the main or the only decisive factor when 
clinicians assess whether patients with treatment resistant schizophrenia are offered to 
commence clozapine treatment 
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Figure legends 
Figure 1.  Age of patients when clozapine treatment was first used (n=195). 
Figure 2.  Proportion of patients that stay on clozapine after latest start of clozapine treatment (n=201)  
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Tables 
Table 1.  Antipsychotic polypharmacy (N=154) 
Daily antipsychotic use   N % *Mean DDD 
Clozapine only   53 34.4% 1.01 
Clozapine plus one additional antipsychotic   70 45.5% 1.79 
Clozapine plus two additional antipsychotics   23 14.9% 2.37 
Clozapine plus three additional antipsychotics   8 5.2% 3.01 
*DDD = Defined daily dose by the World Health Organization       1.67 
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Table 2.  Depot injection used for patients on clozapine (N=154) 
  n % 
*Mean daily dose 
[mg] DDD [mg] 
Perphenazine 10 6.5% 7.3 7 
Risperidone 9 5.8% 3.4 2.7 
Zuclopenthixol 4 2.6% 14.3 15 
Flupentixol 3 1.9% 1.9 4 
Olanzapine 1 0.6% 21.4 10 
  26 16.9%     
 
*The mean daily dose is the depot injection dose divided by the number of days between injections 
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Table 3.  Antipsychotics sold in Iceland in 2013 
  
*DDD [mg] 
Total DDD in 
2013 
Total 
DDD/day Proportion of total sales Drug name 
Quetiapine  400 339.981 931 26.0% 
Olanzapine  10 325.269 891 24.9% 
Risperidone  5 159.052 436 12.2% 
Aripiprazole  15 95.152 261 7.3% 
Clozapine  300 81.750 224 6.2% 
Perphenazine  30 72.593 199 5.5% 
Other 
antipsychotics - 241.672 662 17.9% 
*DDD = Defined daily dose by the World Health Organization 3.604   
 
 
